TCT 846: First-in-Human Treatment of Severe Tricuspid Regurgitation using a novel  Cross-Caval Heterotopic Device

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; Boston Scientific Corporation; Edwards Lifesciences; Venus MedTech